CombiMatrix Announces Plans to Develop microRNA-Based Cancer Screening Assay | GenomeWeb
CombiMatrix this week said that it is developing a test that can screen for multiple cancers simultaneously by measuring miRNA levels in peripheral blood.
 
Taking a page out of the playbooks of miRNA diagnostic developers Exiqon and Rosetta Genomics, CombiMatrix said it will market the array-based test as a homebrew assay available through its own CLIA-certified laboratory. It expects to introduce the test in 18 to 24 months.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.